P-77 A phase II study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma

Abstract

Fibroblast growth factor (FGFR) alterations occur in 10-15% adult patients with advanced cholangiocarcinoma (CCA). Pemigatinib and Infigratinib, the first generation FGFR1-3 kinase inhibitors approved for the treatment of the advanced CCA with FGFR2 gene fusions or other rearrangements, are associated with a median progression-free survival of about 6 months after progression on first-line chemotherapy and acquired resistance is common. A novel spectrum-selective multi-kinase inhibitor, TT-00420, has shown clinical responses in multiple CCA patients bearing the gate-keeper mutations acquired from previous FGFR inhibitor treatment(s) in prior phase I study (NCT03654547).